News

Analysis suggests that OCT is more consistently accurate and sensitive than color imaging and fluorescein angiography, the accepted standards for imaging.

These real-world findings on upadacitinib for atopic dermatitis highlight the drug’s efficacy and survival data among Australian patients.

HCPLive spoke with Cutler on recent phase 3 SOLARIS data and what distinguishes TEV-‘749 from other long-acting injectables.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

A survey reported that among 98.3% of respondents prescribed an epinephrine autoinjector for food allergies, 75.1% expressed concern about obtaining it.

Several mobile apps effectively improved medication adherence in patients with CKD, posing important implications for their impact on clinical outcomes.

Our top 5 headlines spotlight FDA approvals for maralixibat and dupilumab, plus key trial results in diabetes, cardiovascular disease, and retinal vein occlusion.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

Greenspan offers tips in treating seasonal allergies in patients with pulmonary conditions, such as long-COVID, and provides his 2025 spring allergy prediction.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

Class 3 obesity conferred the greatest risk of mortality, complications, and higher resource utilization in alcohol-associated hepatitis hospitalizations.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Dupilumab's approval marks the first new, targeted therapy for CSU in more than a decade and is the 7th indication for a disease with underlying type 2 inflammation.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

This interview in the latest issue of The Respiratory Report features Jamie Hook, MD, discussing research into targeting the lung and not the virus to treat influenza.

This interview in the latest issue of The Respiratory Report features Divay Chandra, MD, MSc, discussing lithium's potential enhancement of alveolar repair after injury.

This interview in the latest issue of The Respiratory Report features William Zhang, MD, discussing AM iron accumulation, which may contribute to the well-known phenomenon of AM dysfunction in COPD6.

This interview in the latest issue of The Respiratory Report features Peter Miller, MD, PhD, discussing the potential role of CH in developing COPD.

Jaime Hook, MD, from Mount Sinai's research aims to develop new therapeutic approaches for influenza lung infection that protect against fatal SA coinfection.

Divay Chandra, MD, MSc, University of Pittsburgh, is evaluating whether higher circulating lithium levels are associated with emphysema in a new study.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.

Jennifer Soung, MD, joins The Medical Sisterhood to discuss her journey to launching LEADderm and how owning the podium has changed her career.

A phase 3 trial found the Viaskin peanut patch effective in desensitizing peanut-allergic children aged 1 – 3 years, regardless of asthma, atopic dermatitis, or other food allergies.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Results indicate that FDD should be accounted for when measuring ganglion cell inner plexiform layer (GCIPL) in eyes with glaucoma.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.